NVO Novo Nordisk A/S
9,881
$128.42
$0.24
(0.19%)
| Watchers | 9,881 |
| 52-Wk Low | $75.56 |
| 52-Wk High | $138.28 |
| Market Cap | $428.72B |
| Volume | 3.08M |
| 52-Wk High | $138.28 |
| 52-Wk Low | $75.56 |
Novo Nordisk struck a $600 million deal to find the next weight loss wonder drugQuartz • 3 days ago
The company behind blockbuster drugs Ozempic and Wegovy wants to keep the gravy train running. Expanding an earlier deal, it announced Thursday that it will pay U.S. company Metaphore Biotechnologies...
Share to Feed
The U.S. Federal Trade Commission (FTC) announced last week that it is, for the second time, disputing hundreds of junk patents listed in the Food and Drug Administration's (FDA) Orange Book, a...
Eli Lilly and Novo Nordisk are boosting supply of their weight loss drugs, while Apple Watch's heart monitoring tech was approved for use in clinical studies...
Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are making encouraging progress on their own treatments...
Five Simple Policies To Reset America's "Rigged" Health System
Calley Means, a one-time consultant for big food and pharmaceutical companies in the Washington, DC, swap and now the...
This is not the first time the tech mogul has seemingly backed the blockbuster drug. Last year, Musk claimed that Ozempic was affecting food sales at Walmart.
read more...
Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market...
If Soranus of Ephesus were alive today he'd be mighty surprised.Like his modern-day counterparts in the medical field, the 2nd Century Greek physician considered obesity to be a disease, and he...
At least 25,000 Americans are beginning treatment with Novo Nordisk's Wegovy each week and that figure is growing, the company said.The Danish pharmaceutical giant, which has been ramping up...
Here Comes Obesity Drug Competition: Amgen Shares Soar On "Very Encouraging" Clinical Trial Update
Amgen's shares soared in premarket trading in New York following the drug maker's...